Related Experiment Videos
Cerestat and other NMDA antagonists in ischemic stroke
1University Department of Medicine & Therapeutics, Western Infirmary, Glasgow, Scotland.
Neurology
|November 26, 1997
Summary
Glutamate antagonists show promise in reducing ischemic stroke injury. Clinical trials are ongoing for agents like aptiganel, focusing on efficacy and patient safety for neuroprotection.
Area of Science:
- Neuroscience
- Pharmacology
- Stroke Research
Background:
- Cerebral ischemia leads to excessive glutamate release, contributing to brain injury.
- Glutamate antagonists offer potential neuroprotection by mitigating ischemic damage.
Purpose of the Study:
- To review the efficacy and tolerability of various glutamate antagonists for treating ischemic stroke.
- To highlight ongoing clinical trials investigating neuroprotective agents.
Main Methods:
- Review of experimental evidence and clinical experience with glutamate antagonists.
- Focus on N-methyl-D-aspartate (NMDA) receptor antagonists, glycine antagonists, and others.
- Analysis of clinical trial designs, patient populations, and outcome measures.
Main Results:
- NMDA receptor antagonists (e.g., aptiganel) show potential neuroprotection but can have side effects.
- Some antagonists (e.g., selfotel, eliprodil) have been discontinued due to risk/benefit ratios.
- Encouraging results with aptiganel, magnesium, and glycine antagonists warrant further large-scale trials.
Conclusions:
- Glutamate antagonism is a viable strategy for neuroprotection in ischemic stroke.
- Continued research and large clinical trials are essential to establish the safety and efficacy of these agents.
- Optimizing drug delivery and patient selection are key for successful neuroprotective therapies.